Skip to main content

memo - Magazine of European Medical Oncology OnlineFirst articles

28.11.2019 | short review

Biomarkers in renal cell carcinoma

We have entered a new era for patients with mRCC with multiple treatment options including VEGF(Vascular Endothelial Growth Factor)-, MET(Mesenchymal-eptihelial Transition)-, AXL(AXL-Rezeptortyrosinkinase)-, mTOR(mechanistic Target of …

OÄ. Dr. Jasmin Terzic, Univ.-Prof. Dr. med. univ. Thomas Bauernhofer

27.11.2019 | short review Open Access

HPV-associated cancers

Human papilloma virus (HPV) is a DNA virus consisting of approximately 8000 base pairs. HPV represents the most common sexually transmitted infection worldwide. Around 200 different genotypes exist. They are distinguished into low- and high-risk …

PhD Dr. Christoph Minichsdorfer

21.11.2019 | short review

ASCO 2019—Personal highlights on adjuvant breast cancer: (neo-)adjuvant therapy of HER2-negative HR-positive BC

This article intends to summarize personal highlights from the 2019 ASCO (American Society of Clinical Oncology) Annual meeting. The article does not aim to offer a comprehensive summary of the 1642 abstracts presented, but rather aims to …

MD, PhD Prof. Semir Beslija

21.11.2019 | short review

Surgery in renal cell carcinoma—when, whom and how?

Surgical resection of RCC should be the aim for cure of localized or locally advanced RCC, either by partial or radical nephrectomy, depending on tumor size and patient’s performance status. In cT1 stages partial nephrectomy is recommended. In …

MD Sebastian Lenart, Ingrid Berger, Nikolaus Hartig, Stephan Madersbacher, Anton Ponholzer

21.11.2019 | short review

First-line treatment of metastatic renal cell carcinoma: current standard of care

The introduction of immune checkpoint inhibitors has further improved response and survival rates in patients with metastatic renal cell carcinoma. In this context, the most promising trial results in the past 12 months include KEYNOTE 426 and the …

MD Assoc. Prof. Martin Marszalek

14.11.2019 | original report

Epidemiology of polycythemia vera in a Mexican population

Clinical presentation, vascular complications, and survival among a 90-patient cohort from a single center

Epidemiology of polycythemia vera (PV) is derived from cohort studies in Western populations. PV studies in the Latin population are limited and have described a lower prevalence of JAK2 mutation. A retrospective cohort of 90 Mexican patients from …

Antonio Olivas-Martinez, Olga Barrales-Benítez, Daniel Montante-Montes-de-Oca, Diana Aguilar-León, Hilda Elizeth Hernández-Juárez, Elena Tuna-Aguilar

14.11.2019 | review Open Access

Role of CAR-T cell therapy in B-cell acute lymphoblastic leukemia

Chimeric antigen receptor (CAR) T cells are genetically engineered cells containing fusion proteins combining an extracellular epitope-specific binding domain, a transmembrane and signaling domains of the T cell receptor. The CD19-CAR T cell …

Univ. Prof. Dr. Hildegard T. Greinix

14.11.2019 | short review

Second-line therapy in metastatic renal cell cancer—how do we treat after immuno-oncology drugs?

The treatment landscape of metastatic renal cell cancer (mRCC) is rapidly evolving. To date in 2019 twelve drugs are licensed for this indication, two more drugs are awaited to be introduced into our portfolio of treatment options by the end of …

MD Ursula Vogl

14.11.2019 | short review

Management of nonmetastatic muscle invasive bladder cancer in the elderly

A substantial increase in the number of elderly patients with muscle invasive bladder cancer (MIBC) is expected in upcoming years due to demographic changes and the peak incidence of bladder cancer in the 8th decade of life. The management of …

MD, FEBU Prof. Stephan Madersbacher

12.11.2019 | review Open Access

ASCO 2019: highlights in HER2-positive metastatic breast cancer

At the 2019 ASCO (American Society of Clinical Oncology) Annual Meeting, several interesting trial results were presented in the field of HER2-positive metastatic breast cancer. The end-of-study analysis of the pivotal CLEOPATRA trial indicated an …

Rupert Bartsch, Elisabeth Bergen

11.11.2019 | short review

Evidence-based follow-up in renal cell carcinoma

The optimal surveillance strategy in renal cell carcinoma after curative resection or ablation is a field of ongoing research. This review discusses the evidence behind routine follow up, duration of follow up, imaging modality and intervals as …

MD Karl Mayrhofer, MD, MBA Dora Niedersüß-Beke

08.11.2019 | short review Open Access

Molecular profiling in gastroesophageal cancer—clinical routine and future perspective

Although several large clinical trials have been conducted in order to investigate targeted inhibition of several molecular pathways in gastric cancer, only a limited number of targeted therapies have been introduced in clinical routine. Besides …

MD Hannah Christina Puhr, MD, PhD Aysegül Ilhan-Mutlu

06.11.2019 | short review Open Access

Targeted therapy in lung cancer—ASCO 2019 update

New targeted therapies for patients with non small cell lung cancer were presented at this year’s ASCO. EGFR exon 20 insertions might soon be treatable with TAK-788, which showed an objective response rate (ORR) of between 25 and 56% with a …

M.D., Ph.D. Romana E. Wass, M.D. David Lang, M.D. Bernd Lamprecht, M.D. Michael Studnicka

06.11.2019 | short review

Current trends in small cell lung cancer management—ASCO 2019 update

During the last 30 years the developments in small cell lung cancer (SCLC) have been extremely scarce. Concurrent chemo-radiation associated with prophylactic cranial irradiation in case of complete clinical remission is standard in limited …

MD, PhD Mircea Dediu

06.11.2019 | original report Open Access

Prevalence of comorbidity in cancer patients scheduled for systemic anticancer treatment in Austria

A cross-sectional multicentre observational study

The purpose of this observational study was to determine the prevalence of comorbid conditions in cancer patients with solid tumours selected for specific treatment at 12 divisions of medical oncology in Austria. Data from 1137 patients were …

MDPhD Assoc. Prof. Marija Balic, Wolfgang Hilbe, Sylvia Gusel, Michael Fiegl, Heinz Ludwig, Beate Mayrbäurl, Josef Thaler, Hellmut Samonigg, Karin Hegenbarth, Florian Eisner, Brigitte Mlineritsch, Richard Greil, Maria Johanna Schandl, Ansgar Weltermann, Andreas Petzer, David Fuchs, Wolfgang Stangl, Peter Krippl, Reinhard Stauder, Herbert Stöger

28.10.2019 | short review

Advanced/metastatic urothelial carcinoma of the bladder and upper urinary tract

Presentation highlights from the ASCO 2019 Congress

Three important oral presentations from the ASCO 2019 congress concerning advanced and metastatic urothelial carcinoma of the urinary bladder and the upper tract are highlighted and their potential clinical implications for the improvement of …

MD Assoc. Prof. Georg C. Hutterer, MD Assoc. Prof. Martin Pichler

24.10.2019 | short review

Evidence-based follow-up for breast cancer

Short review

A large number of medical societies have issued recommendations for follow-up after primary treatment for early breast cancer, which mostly differ only in the details. The central statement in all of these guidelines has been based on two studies …

Michael Stierer

23.10.2019 | short review Open Access

Neoadjuvant therapy in urothelial cancer

New therapies on the horizon

Neoadjuvant cisplatin-based chemotherapy is standard treatment for muscle-invasive bladder cancer before radical cystectomy (RC). Despite level 1 evidence demonstrating an overall survival benefit for patients undergoing RC after neoadjuvant …

Stephan Brönimann, David D’Andrea, Shahrokh F. Shariat, MD Kilian M. Gust

15.10.2019 | short review Open Access

Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer

The best of ASCO 2019

Early stage HER2-positive cancer outcomes have been substantially improved over the last two decades, but there is still some potential for improvement. Several studies on the preoperative/postoperative treatment of HER2-positive breast cancer …

Christoph Suppan, Marija Balic

27.09.2019 | short review Open Access

Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?

To date, intravesical instillation of Bacillus Calmette–Guérin (BCG) is the standard adjuvant treatment for most intermediate- and all high-risk bladder nonmuscle invasive urothelial carcinomas (NMIBC) after complete transurethral resection.

Stephan Brönimann, Shahrokh F. Shariat, Melanie R. Hassler